Lack of Correlations among Histopathological Parameters, Ki-67 Proliferation Index and Prognosis in Pheochromocytoma Patients |
Ocal, Irfan
(Departmant of Pathology, Katip Celebi University Ataturk Education and Research Hospital)
Avci, Arzu (Departmant of Pathology, Katip Celebi University Ataturk Education and Research Hospital) Cakalagaoglu, Fulya (Departmant of Pathology, Katip Celebi University Ataturk Education and Research Hospital) Can, Huseyin (Departmant of Pathology, Katip Celebi University Ataturk Education and Research Hospital) |
1 | Ernest E. Lack (2007). Tumors of the adrenal gland. In 'Diagnostic Histopathology of Tumors 3rd Edition', Eds Christopher D.M. Fletcher. Elsevier Ltd, Philadelphia pp 1109-15. |
2 | Harrison LE, Gaudin PB, Brennan MF (1999). Pathologic features os prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg, 134, 181-5. DOI |
3 | Kimura N, Miura W, Noshiro T, et al (1994). Ki-67 is an indicator of progression in neuroendocrine tumours. Endocr Pathol, 5, 223-8. DOI |
4 | Strong VE, Kennedy T, Al-Ahmadie H, et al (2008). Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery, 143, 759-68. DOI ScienceOn |
5 | Linnoila RI, Keiser HR, Steinberg SM, et al (1990). Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Patol, 21, 1168-80. DOI ScienceOn |
6 | Nagura S, Katoh R, Kawaoi A, et al (1999). Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. Mod Pathol, 12, 1107-11. |
7 | Rosai J (2011). Pheochromocytoma. In 'Surgical Pathology 10th Edition', Eds Rosai and Ackermans. MOSBY Elsevier Inc. pp 1076-8. |
8 | Szalat A, Fraenkel M, Doviner V, et al (2011). Malignant pheochromocytoma: Predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocrine, 39, 160-6. DOI ScienceOn |
9 | Thompson LD (2002). Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol, 26, 551-66. DOI ScienceOn |
10 | de Wailly P, Oragano L, Rade F, et al (2012). Malignant pheochromocytoma: new malignancy criteria. Langenbecks Arch Surg, 397, 239-46. DOI |
11 | Clarke MR, Weyant RJ, Watson CG, et al (1998). Prognostic markers in pheochromocytoma. Hum Pathol, 29, 522-6. DOI |
12 | DeLellis RA, Lloyd RV, Heitz PU, et al (2004). World Health Organization Classification of Tumours Pathology & Genetics. Tumours of Endocrine Organs, 151-5. |
13 | Agarwal A, Mehrotra PK, Jain M, et al (2010). Size of the tumor and Pheochromocytoma of the Adrenal Gland Scaled Score (PASS): Can They Predict Malignancy? World J Surg, 34, 3022-8. DOI ScienceOn |
14 | van der Harst E, Bruining HA, Jaap Bonjer H, et al (2000). Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol, 191, 175-80. DOI |
15 | Wu D, Tischler AS, Lloyd RV, et al (2009). Observer variation in the application of the pheochromocytoma of adrenal Gland Scaled Score. Am J Surg Pathol, 33, 599-608. DOI |